Biology of Juvenile Myoclonic Epilepsy
Start Date
7/13/2017
Completion Date
12/31/2026
Summary
The investigators are collecting genetic information through blood samples as well as clinical and EEG data from over 1000 people with Juvenile Myoclonic Epilepsy (JME) across the UK, Europe and North America. This study will draw on both existing and new samples from JME patients. These will be compared to anonymised data from samples for 2000 controls. The goal of this study is to find the genetic cause of JME. Finding the cause will help create better treatments for JME, as well as improve patient outcomes by allowing us to detect it earlier.
Detailed Description
Epilepsy is a common neurological disorder affecting 1% of the population. There are over 30 types of epilepsy, some common, some rare. Most epilepsies arise in childhood and have a genetic cause. Approximately 40% of patients have the common forms of Genetic Generalised Epilepsy (GGE), and the commonest GGE is "Juvenile Myoclonic Epilepsy" or JME. The goal of this study is to find the genetic cause for JME. The investigators will do this by comparing the genetic code in JME patients with that in people who do not have epilepsy. This study will use clues from their electroencephalograph or brainwave test that is used to help diagnose epilepsy. Participants will provide a single blood sample, along with permission to collect clinical data about their diagnosis and a copy of their clinical EEG. There is no direct benefit or risk to the research participants but the results from this study may help other people with epilepsy or brain impairments in the future. There is overwhelming evidence that JME is caused by changes in genetic code. These changes are likely to be found in more than just one gene and there may be more than one type of change. In order to find these changes, this study will look at a large number of people with JME and compare their genetic code with people who do not have epilepsy. Finding the causes of JME will lead to better understanding of its cause, new treatments, and tailoring of treatments according to a person's genetic make-up.
Eligibility Criteria
Age Range: 10 years to 40 years
Interventions
Blood draw
Existing samples
Conditions
Locations
Mount Sinai-Beth Israel Medical Center
New York, New York 10003
United States
St Luke's Roosevelt Hospital
New York, New York 10025
United States
Nationwide Children's Hospital
Columbus, Ohio 43125
United States
Hospital for Sick Kids
Toronto, Ontario M5G 0A4
Canada
Charles University
Prague, 116 36
Czechia
Danish National Epilepsy Centre
Dianalund, 4293
Denmark
Tallinn Children's Hospital
Tallinn, 13419
Estonia
University Robert Debré
Paris, 75019
France
Commissione Genetica Lega Italiana contro l'Epilepssia
Roma, 00198
Italy
Vestre Viken Health Trust, Oslo
Drammen, 3004
Norway
Walton Centre for Neurology and Neurosurgery
Liverpool, L9 7LJ
United Kingdom
Royal London Hospital
London, E1 1BZ
United Kingdom
St Thomas' Hospital
London, SE1 9HT
United Kingdom
King's College Hospital NHS Trust
London, SE5 9RS
United Kingdom
Swansea University
Swansea, SA2 8PP
United Kingdom